Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Operating Leases: 2019-2025

Historic Operating Leases for Cumberland Pharmaceuticals (CPIX) over the last 6 years, with Sep 2025 value amounting to $5.0 million.

  • Cumberland Pharmaceuticals' Operating Leases fell 7.27% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 7.27%. This contributed to the annual value of $5.3 million for FY2024, which is 6.17% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Operating Leases of $5.0 million as of Q3 2025, which was down 2.02% from $5.1 million recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Operating Leases peaked at $5.8 million during Q2 2023, and registered a low of $229,605 during Q3 2022.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Operating Leases value was $5.4 million (recorded in 2024), while the average stood at $5.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 82.66% in 2022, then spiked by 2,392.62% in 2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' Operating Leases (Quarterly) stood at $1.1 million in 2021, then spiked by 349.11% to $4.8 million in 2022, then increased by 18.60% to $5.6 million in 2023, then fell by 6.17% to $5.3 million in 2024, then dropped by 7.27% to $5.0 million in 2025.
  • Its Operating Leases stands at $5.0 million for Q3 2025, versus $5.1 million for Q2 2025 and $5.2 million for Q1 2025.